Cost effectiveness of pharmacogenetic screening prior to initiation of carbamazepine treatment for epilepsy

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

StandardStandard

Cost effectiveness of pharmacogenetic screening prior to initiation of carbamazepine treatment for epilepsy. / Plumpton, C. O.; Yip, V; Alfirevic, A. et al.
Yn: Value in Health, Cyfrol 16, Rhif 7, 11.2013, t. A624-A624.

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

HarvardHarvard

APA

CBE

MLA

VancouverVancouver

Plumpton CO, Yip V, Alfirevic A, Marson A, Pirmohamed M, Hughes D. Cost effectiveness of pharmacogenetic screening prior to initiation of carbamazepine treatment for epilepsy. Value in Health. 2013 Tach;16(7):A624-A624. doi: 10.1016/j.jval.2013.08.1831

Author

Plumpton, C. O. ; Yip, V ; Alfirevic, A. et al. / Cost effectiveness of pharmacogenetic screening prior to initiation of carbamazepine treatment for epilepsy. Yn: Value in Health. 2013 ; Cyfrol 16, Rhif 7. tt. A624-A624.

RIS

TY - JOUR

T1 - Cost effectiveness of pharmacogenetic screening prior to initiation of carbamazepine treatment for epilepsy

AU - Plumpton, C. O.

AU - Yip, V

AU - Alfirevic, A.

AU - Marson, A.

AU - Pirmohamed, M.

AU - Hughes, Dyfrig

PY - 2013/11

Y1 - 2013/11

U2 - 10.1016/j.jval.2013.08.1831

DO - 10.1016/j.jval.2013.08.1831

M3 - Article

VL - 16

SP - A624-A624

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 7

ER -